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ABSTRACT
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OLIGONUCLEOTIDE DELIVERY SYSTEMS
FOR CAMPTOTHECINS

Numerous attempts have, of course, been made to address
these problems and shortcomings. To date, one of the most

This is a National Stage Application under 35 U.S.C.

successful Ways for maintaining camptothecin drugs in the
antitumor-active lactone form is by stabiliZation of the drug

§371 of International Application No. PCT/US98/20941,

in macromolecular lipid or surfactant assemblies such as

liposomes or micelles, The liposomal or micellular stabili
Zation of camptothecins is described in detail in US. Pat.
Nos. 5,552,156 and 5,736,156 both to Burke. Speci?cally,

?led on Oct. 14, 1998.
This invention Was made With Government support
under NIH grant NIH CA: 63653. The Government may

have certain rights in this invention.
10

TECHNICAL FIELD

surfactant monolayer membrane of the micelles. The
liposome-bound or micelle-bound drug is protected from

The present invention relates generally to camptothecin
anticancer drugs and the use of oligonucleotides to bind

selectively the lactone forms of camptothecins, thereby
conserving the agents in their biologically active lactone

hydrolysis, thus preserving the antitumor activity of the
15

BACKGROUND OF THE INVENTION

Camptothecin, a plant alkaloid isolated from trees indig

9-aminocamptothecin, 9-nitrocamptothecin,
10-hydroxycamptothecin,
10,11

20

methylenedioxycamptothecin, 9-nitro- 10,1 1 methylenedioxycamptothecin, 9-chloro-10,11 -

methylenedioxycamptothecin, 9-amino-10,11
methylenedioxycamptothecin,

25

7-ethyl- 10

hydroxycamptothecin (SN-38), topotecan, DX-8951,
GG211, 7-trimethylsilylmethylcamptothecin, and other ana
logues (collectively referred to herein as camptothecin
drugs) are presently under study WorldWide in research

thus disassociate from the liposomal membrane to reside in
the interior of liposome, the pH of the internal environment

of the liposome is reduced thereby preventing hydrolysis of
the camptothecin drug. Camptothecin drugs are also stabi
liZed by association With micelles comprised of surfactants
such as sodium dodecylsulfate (SDS), octylphenolpolyoxy
ethylene glycol and sorbitan mono-oleate.
Recently the effectiveness of liposomal topotecan formu
lations Were evaluated in animal models. Although topote
can exhibits good clinical activity against a variety of tumor

30

laboratories and cancer clinics. In lab tests and in clinical

trials, these camptothecin drugs have aroused considerable
interest as a result of their ability to halt the groWth of a Wide

range of human tumors. For example, these drugs exhibit

unprecedented high levels of antitumor activities against

drug.
The liposome is comprised of lipids such as, for example,
phospholipids or cholesterol. For the camptothecin drugs
Which have a lower affinity for the liposome membrane and

forms.

enous to China, and analogues thereof such as

the lactone ring of the camptothecin drugs is stabiliZed in the
membrane of the vesicles. Typically, the camptothecin drugs
bind the lipid bilayer membrane of the liposome and the

types, it undergoes rapid hydrolysis in vivo from the active,
lactone species to the inactive carboxylate. This inactivation,
coupled With cell-cycle-speci?c behavior and fairly rapid
elimination, results in highly schedule-dependent clinical
activity. Liposomal carriers accumulate selectively at tumor
sites and can potentially act as sustained release systems

35

maintaining therapeutic drug levels over a prolonged period.

human colon cancer [Giovanella, et al. Science 246:

In the case of topotecan, such carriers might also protect the

1046—1048 (Wash. DC.) (1989)]. Camptothecin has also

drug in its lactone form until released. A procedure Whereby

been shoWn to be effective against other experimental cancer

topotecan could be efficiently encapsulated Within lipid
based carriers employing an ion gradient loading procedure

types such as lung, breast, and malignant melanoma.
Camptothecin is thought to inhibit the proliferation of
cancer cells by interfering With the breakage/reunion reac
tion of the enZyme topoisomerase I, a nuclear enZyme

and delivered to tumors has been developed (Madden et al.,
1998). In contrast to earlier studies on liposomal delivery in
Which camptothecins Were inserted predominantly into the

implicated in DNA replication and RNA transcription. A

lipid bilayer, the current technique entraps topotecan in the

40

camptothecin drug stabiliZes and forms a reversible enZyme

camptothecin-DNA ternary complex, designated the cleav

aqueous core of the carrier. Drug uptake Was rapid

limited by their chemical properties. First, the camptothecin

(approximately 60 min. at 60° C.) and high encapsulation
ef?ciencies (>95%) Were readily achieved at relatively high
drugzlipid ratios (0.1:1 mole ratio). Plasma elimination rates
Were compared for free topotecan and encapsulated drug
(liposomal topotecan) in mice. FolloWing a bolus intrave
nous injection (lateral tail vein) at 10 mg/kg, plasma level

drugs are insoluble in Water Which hinders the delivery of

Were folloWed for up to 24 hours. Plasma levels of topotecan

the drug to the cancer cells. Second, the camptothecin drugs

given in the liposomal formulation Were approximately tWo
orders of magnitude higher than for free drug over this
timecourse. Further, by employing carriers With an acidic
interior the entrapped topotecan Was protected as the lactone
species (85% lactone at 24 hours). Antitumor ef?cacy Was
compared for free and liposomal topotecan in the murine

45

age complex. The formation of the cleavable complex
speci?cally prevents the reunion step of the breakage/union
cycle of the topoisomerase reaction.
HoWever, the clinical use of the camptothecin drugs is

are extremely susceptible to hydrolysis; in an aqueous
environment such as blood plasma, the half life is about 16
to 20 minutes and active lactone concentrations can fall to 55

almost negligible levels depending upon the analogue. The
camptothecin drugs each contain a substituted quinoline
nucleus (rings A—C) and, at the opposite end an ot-hydroxy
lactone ring Which is very unstable in aqueous environ
ments. In blood plasma the ring is quickly opened to create
the carboxylate form of the drug, Which is poorly accumu
lated by cancer cells. Once internaliZed by the cancer cells,
the carboxylate form exhibits no activity against its molecu

L1210 model (i.p. tumor inoculation/i.v. treatment) using
either a single bolus injection on day 1 (10 or 20 mg/kg), or
60

lar target, topoisomerase I. Thus, the hydrolyZed product is
ineffective at treating cancer. Moreover, the hydrolyZed
product appears to be more toxic to healthy tissue than the

camptothecin drugs.

65

bolus injections on days 1, 5, 9 (4 or 8 mg/kg). In all
treatment schedules liposomal topotecan exhibited much
greater antitumor activity than did free drug.
While the liposomal and micellar stabiliZation of camp
tothecin drugs described in US. Pat. Nos. 5,552,156 and
5,736,176 to Burke address and effectively overcome the

instability and insolubility problems of camptothecin drugs
administered in their free form, further improvements lead

US 6,897,200 B1
3

4

ing to more efficient, diversi?ed and effective administration

dsDNA, but no effect on the active lactone drug concentra

and treatment of tumors and various cancer types are still

tions Were reported (Fukada et al., Biochemical Pharmacol
ogy 34: 1225—1230 (1985); Leteurtre et al., Biochemistry 32:

possible and are actively being sought.

8955—8963 (1993)). Until We completed our studies it Was
not knoWn that camptothecins can bind to DNA and these
interactions act to conserve the active lactone forms of these
medications (Yang et al. J. Am. Chem. Soc. 120: 2979—2980

ToWard that end, We have developed the present inven
tion. Speci?cally, We have found that direct noncovalent

binding interactions of camptothecin drugs With oligonucle
otides conserve the active forms of the drugs (i.e. the active
lactone forms of camptothecin drugs are found to be stable

(1998).
The present invention relates generally to camptothecin

When complexed With oligonucleotides). The oligonucle
otides include single-stranded DNA, double-stranded DNA,

anticancer drugs and the use of oligonucleotides to bind

selectively the lactone forms of camptothecin drugs. The

antisense DNA, RNA, and catalytic RNA. The invention

binding interactions act to conserve the agents in their

describes macromolecular assemblies Which include both
viral or non-viral oligonucleotide vectors. The viral gene

delivery systems include retroviruses, adenoviruses, adeno
associated viruses, Herpes viruses, Vaccinia viruses, and
other virus particles. The non-viral delivery systems include

biologically-active lactone forms. Direct noncovalent bind
ing interactions of a camptothecin drug of SN-38 lactone
15

transfection vehicles, naked DNA for injection, gene gun

When complexed With oligonucleotides).
The oligonucleotides include single-stranded DNA,
double-stranded DNA, antisense DNA, RNA, and catalytic

particles, liposomes including cationic liposomes,
virosomes, receptor-mediated delivery vehicles, and biode
gradable and non-biodegradable polymer matrixes. The

RNA, among others. This invention describes macromo
lecular assemblies Which include both viral or non-viral

macromolecular assemblies can consist of the folloWing

materials: biodegradable and non-biodegradable polymers,
lipids, carbohydrates, proteins and biologically relevant
molecules Which facilitate the delivery, accumulation and

processing of the oligonucleotides and drugs to target tissues
Within the human body. Each of the above oligonucleotide

25

delivery vectors contain oligonucleotides Which act to sta
nucleotide contained Within the vectors can serve as a

stabiliZing matrix for the drug and the stabiliZation can be

Camptothecin drugs complexed in a reversible manner to

effective over a Wide pH range, the vectors also provide a

oligonucleotides (for both Water-soluble oligonucleotide
camptothecin drug complexes or oligonucleotide

means for the controlled, targeted and stable delivery of
camptothecin drug to target tissue. In addition to stabiliZing
camptothecin, the oligonucleotides carried in the vectors

camptothecin drug complexes contained in particles such as
35

virus particles) can gain entry into cancer cells. Because the

drugs are reversibly complexed With the oligonucleotides,
the drugs can dissociate from the oligonucleotides and be
able to exert their effect on the topoisomerase I target Within

tissue and the patient receiving the therapy. The combination
of stable camptothecin drug delivery and gene therapy can
have potentially unique and desirable consequences on
inhibiting the spread of cancer and other disease states in
humans and animals.

oligonucleotide vectors. The viral gene delivery systems
include retroviruses, adenoviruses, adeno-associated
viruses, Herpes viruses, Vaccinia viruses, and other virus
particles. The non-viral delivery systems include transfec
tion vehicles, naked DNA for injection, gene gun particles,

liposomes including cationic liposomes, virosomes,
receptor-mediated delivery vehicles, and biodegradable and
non-biodegradable polymer matrixes.

biliZe the lactone forms of camptothecin drugs. The oligo

serve an additional role in exerting gene therapy or phar
macological effects in general Which can be envisioned to
augment the effects of camptothecins on the host target

With oligonucleotide is described here. The interactions are
found to conserve the active forms of the drugs (i.e. the
active lactone forms of camptothecins are found to be stable

the cancer cell. In the special case Where covalent interac
40

tions betWeen camptothecin drug and oligonucleotide put
the drug in closer proximity to the macromolecule, such that
the probability of lactone binding and stabiliZation is greater,
cellular metabolism Will be necessary to release the drug

SUMMARY OF THE INVENTION

Accordingly, it is a primary object of the present invention

45

to provide stable, Water soluble, highly pharmacologically
active camptothecin drugs overcoming the above described

acteristics. The oligonucleotide-DNA complexes can consist
of the folloWing materials: biodegradable and non

limitations and disadvantages of the prior art including the

instability and insolubility problems of camptothecin drugs

biodegradable polymers, lipids, carbohydrates, proteins and

administered in free form.

Still another object of the present invention is to provide
camptothecin drugs formed in complex With an oligonucle
otide including DNA and RNA Wherein the formation of the
complex results in binding interactions betWeen the active
lactone form of the drug and the oligonucleotide.
The prior art concerning camptothecin interactions With

from the oligonucleotide.
The oligonucleotide-camptothecin drug complexes can be
further incorporated into macromolecular assemblies for
optimiZation of controlled drug release and delivery char

biologically relevant molecules Which facilitate the delivery,
accumulation and processing of the oligonucleotides and
drugs to target tissues Within the human body. Each of the

above oligonucleotide delivery vectors containing oligo
55

nucleotides can act to stabiliZe the lactone forms of camp

tothecin drugs. The oligonucleotide contained Within the

DNA indicated that there Was only very limited direct

vectors can serve as a stabiliZing matrix for the drug and the
stabiliZation can be effective over a Wide pH range; the

experimental evidence that camptothecin and its analogs/

vectors also provide a means for the controlled, targeted and

derivatives bind to oligonucleotides such as DNA in the

stable delivery of camptothecin drug to target tissue. In
addition to stabiliZing camptothecin, the oligonucleotides

absence of the t+opoisomerase I protein. Earlier Work sug
gests that camptothecin derivatives bind to neither isolated

carried in the vectors serve an additional role in exerting

DNA structures nor isolated topoisomerase I; the researchers

gene therapy or pharmacological effects in general Which

indicated that the drug only binds to the DNA

topoisomerase 1 complex (HertZberg et al., J. Biol. Chem.
265: 19287—19295 (1990)). Other studies have suggested
that camptothecin drugs may Weakly interact With intact

can be envisioned to augment the effects of camptothecins
65

on the host target tissue and the patient receiving the therapy.
The combination of stable camptothecin drug delivery and
gene therapy can have potentially unique and desirable

US 6,897,200 B1
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6

consequences on inhibiting the spread of cancer and other
disease states in humans and animals.

Topotecan (1 pM ?nal concentration) Was incubated in PBS,
pH 7.4 either alone (?lled circles) or in the presence of 10
mg/ml of RNA (open circles) at 22° C. and analyZed for the
fraction of lactone present at different times by reversed
phase HPLC. The ?gure indicates that in the presence of 10
mg/ml of RNA, 25% more of the lactone form of topotecan
is present after 3 hrs.
FIG. 7 represents a comparison of the stability of topo

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawing incorporated in and forming
a part of the speci?cation, illustrates several aspects of the
present invention and together With the description serves to

explain the principles of the invention. In the draWing:
FIG. 1 is a summary of the structures of several clinically

tecan in the presence and absence of RNA at 37° C.
10

relevant camptothecins including camptothecin (CPT), CPT
11, SN-38, and topotecan (TPT). Also shoWn at the bottom
of the ?gure are the D and E rings of the drugs, With the

depiction shoWing the pH-dependent conversion betWeen
the lactone and carboxylate forms of the drug. At physi
ological pH the carboxylate form of the drug is by far the
predominant form of the drug.

15

ence of 10 mg/ml of RNA, 15% more of the lactone form of

20

topotecan is present after 3 hrs.
FIG. 8 depicts the marked shifting of the ?uorescence
emission spectra of SN-38 lactone (1 MM ?nal
concentration) in the presence of double-stranded DNA
(dsDNA). SN38 contains a 10-hydroxy-nctionality Which
results in the molecule having a ?uorescence emission
Which is highly sensitive to the presence of Water in the
surrounding microenvironment. The inset of the ?gure
shoWs the dramatic shifting of the ?uorescence of the

FIG. 2 represents a kinetic evaluation of the rate of

lactone ring opening for topotecan (left panel) and CPT-11
(right panel) in the presence and absence of duplex DNA
oligonucleotides ((dG-dC)5 or (dA-dT)15). Data for drug in
the absence of DNA (triangles), drug in the presence of

(dG-dC)15 (solid circles) or (dA-dT)15 (open circles) are
shoWn. All experiments Were conducted in phosphate buff

ered saline (PBS) (pH 7.40:0.05) at room temperature. Drug

25

and DNA concentrations of 10 pM and ~30 mM base,

respectively, Were employed. Each pro?le represents the
average of at least three independent kinetic runs With the
same sampling schedules. The standard deviation of each
point Was typically 5% or less. Kinetic parameters for the
various samples are summariZed in Table 1.
FIG. 3 represents a kinetic evaluation of the rate of

molecule When Water is excluded from the microclimate of
the ?uorophore. Note hoW the agent ?uoresces in the 410 nm
to 460 nm region When Water is not present, but ?uoresces
at 520 to 530 nm When Water is present. Note hoW the

?uorescence of SN38 lactone shifts markedly to loWer
30

Wavelength upon interacting With double-stranded DNA,
clearly indicating that the agent is capable of directly
interacting With the DNA. These data indicate that by
interacting With DNA, the ?uorophore can relocate to dif

lactone ring opening for topotecan and CPT-11 in the
presence of various concentrations of duplex DNA oligo

nucleotides (GC15 and AT15) and single-strand DNA (dT)3O.

Topotecan (1 pM ?nal concentration) Was incubated in PBS,
pH 7.4 either in the absence (?lled circles) or in the presence
of 10 mg/ml of RNA (open circles) at 37° C. and analyZed
for the fraction of lactone present at different times by
reversed-phase HPLC. The ?gure indicates that in the pres

35

ferent microenvironment With markedly reduced Water con
tent. The ?uorophore Was directly added to the DNA solu

All experiments Were conducted in PBS (pH 7.40:0.05) at
room temperature. Drug concentrations of 10 pM and DNA

prior to any signi?cant conversion of the agent to carboxy

concentrations of 30 mM base for dsDNA and 33 mM base

late form.

tion and the spectra recorded immediately (Within 2 min.)

for ssDNA (dT)3O Were employed. Each pro?le represents
the average of at least three independent kinetic runs With
the same sampling schedules. The standard deviation for

40

each point is typically 5% or less. Standard deviations in the
kinetic results When using different DNA synthetic batches

FIG. 9 shoWs the UV absorption spectra of topotecan

lactone (left panel) and CPT-11 lactone (right panel) in the
absence and presence of duplex DNAoligonucleotides ((dG
dC)15 or (dA-dT)15) in PBS (pH 500x005 at room

temperature). Drug, (dG-dC)15, and (dA-dT)15 concentra

can range up to 10%. Kinetic parameters for the various
tions of 10 pM, 16 mM base, and 24 mM base, respectively,
45
samples are summariZed in Table 1.
Were employed.

FIG. 4 depicts the stability of topotecan in the presence of

FIG. 10 shoWs NMR spectra depicting the titration of (A)
CPT-11 to d(CGTACG) at pH 7.0, 20° C. and (B) TPT

various concentrations of RNA at 22° C. In these

experiments, topotecan (at a ?nal concentration of 1 pM)

lactone to d(CGTACG) at pH 5 at 20° C. The ratios shoWn
in the ?gure are for drug/DNA.
FIG. 11 contrasts the changes in the 1H NMR resonances
for both free drug and nascent DNA versus 2:1 drug DNA
complexes. Not hoW the chemical resonances of both the

Was incubated in PBS, pH 7.4 in the presence of various
concentrations of RNA (total RNA from yeast) for 30 min at

22° C. and analyZed for the fraction of lactone present by
reversed-phase HPLC. The ?gure indicates that the presence
of RNAprovides a means of enhancing the amount of active
lactone form of the drug. As an example, in the presence of
7.5 mg/ml of RNA there exists a 10% greater amount of the
lactone form than found in the absence of RNA.

FIG. 5. Stability of topotecan in the presence of various
concentrations of RNA at 37° C. Topotecan (1 pM ?nal
concentration) Was incubated in PBS, pH 7.4 in the presence
of various concentrations of RNA (total RNA from yeast) for

drug and DNA shift up?eld upon complex formation.
55
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FIG. 6 represents a comparison of the stability of topo
tecan in the presence and absence of RNA at 22° C.

Camptothecin drugs are a family of agents Which exhibit
very high potencies against a Wide and diverse range of
tumor types and thus camptothecin drugs are useful anti
cancer agents. LikeWise, oligonucleotides can be used as
effective anticancer drugs. Cancer has been shoWn to be a

30 min at 37° C. and analyZed for the fraction of lactone
present by reversed-phase HPLC. At a RNA concentration
of 7.5 mg/ml, 12% more of the lactone form of topotecan is

present.

DETAILED DESCRIPTION OF THE
INVENTION

somatic genetic disorder With gene dysfunctions that accu
mulate as the tumor progresses from premalignant lesions to
65

malignant transformations. Oligonucleotides containing
genetic information can be transferred to speci?c target cells
in the body to prevent and limit the spread of cancer cells.

US 6,897,200 B1
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This technology, Widely referred to as gene therapy, requires

The oligonucleotide Which stabiliZes the camptothecin
drug of interest can be any of the folloWing general types:
B-Form DNA, A-Form DNA, C-Form DNA, D-Form DNA,
T-Form DNA, Z-DNA, double-stranded DNA: single
stranded DNA, negatively-supercoiled DNA, nicked DNA,
positively-supercoiled DNA, plasmid DNA, circular or

the oligonucleotide or genes and their regulatory elements as
Well as vectors such as cationic liposomes or adenoviruses

to introduce the genes into the patients target cells for

therapeutic activity.
There are several reasons Why combination camptothecin

drug-gene therapy dosage forms may prove to be promising
technologies for cancer treatment. Hematologic malignan
cies and solid tumors contain cells that are highly responsive
to the presence of camptothecin drugs. As a result of the

cDNA, interWound or toroidal coiled DNA, catenaned or

knotted DNA, helical DNA, hairpin DNA, interstrand
crosslinked DNA, DNA in Cruciform structures, intermo
10

stable delivery of the bioactive lactone forms of camptoth
ecin drugs facilitated by the presence of the oligonucleotide,

somal DNA, chromosomal DNA, antisense

tumor siZe can be reduced and the spread or metastasis of the
tumor can be halted. A number of genetic mechanisms of

cancer development and progression have been discovered,

leading to genetic, oligonucleotide-based therapies for treat

oligonucleotides, riboZymes, triplex-forming
oligonucleotides, nuclease-resistant DNA therapeutics, self
15

ment. The combination of the tWo therapeutic substances,

ester and chimeric oligonucleotides, protein-antisense oli

gonucleotide conjugates, antibody-antisense
20

alphavirus DNA, mitochondrial DNA, DNA plasmid shuttle

the camptothecin therapy by modulating cytokine/

vectors, hammerhead riboZymes, hairpin riboZymes, oligo
25

nucleotide cleaving riboZymes, antisense RNA, viral vector
DNA, pararetroviral and retroviral DNA, N-linked oligosac
caride DNA, self-splicing group 1 intron riboZymes, self
splicing group II intron riboZymes, ribonuclease P(RNAase

30

riboZymes,
anti-HIV
riboZymes,
oliogdeoxyribonucleotide, and catalytic DNA.

genes, and drug resistance genes, and genes involved in

angiogenesis. While the presence of the oligonucleotide
serves as a stabiliZing matrix Where noncovalent binding

interactions stabiliZe the camptothecin drug in the active
lactone form, the oligonucleotide also can have a therapeutic
effect that can enhance, prolong, and have a desirable

P) riboZyme, hepatitis delta virus riboZymes, hairpin

combined effect With the camptothecin drug. Other objects
and advantages of the present invention involving
oligonucleotide-camptothecin drug formulations Will
become apparent as to the description thereof proceeds.

raf

The nucleic acids Which are useful in the present inven
tion are those that form drug-oligonucleotide complexes in
solution as Well as those that form drug-oligonucleotide
35

Typically, viral or non-viral vectors are used to deliver the

gene therapy oligonucleotides to target cancer cells. The
viral vectors include the folloWing: retroviruses,

complexes in non-viral or viral delivery vehicles. The
nucleic acids are typically nucleotide polymers having from
10 to 500,000 nucleotide residues. Typically, the nucleic
acids of interest are to be administered to a subject for the

adenoviruses, adeno-associated viruses, Herpes viruses,
Vaccinia viruses, and polioviruses. The non-viral vectors
include transfection, naked DNA injection, gene gun, direct

oligonucleotide conjugates, messenger RNA, Hoogsteen

DNA, phosphorothioate oligonucleotides, phosphodiester
oligonucleotides, methylphosphonate oligonucleotides,

oligonucleotide-based gene therapy can potentially augment
immunotherapy, drug sensitivity genes, tumor suppressor

assembled oligonucleotides as antisense agents, circular
oligonucleotides, peptide nucleic acids, stabiliZed RNA ana

logs for antisense and riboZyme applications, phosphodi

active lactone camptothecin drugs and oligonucleotides,
provide signi?cant advantages at inhibiting the progression
of solid tumors and hematologic malignancies. Whereas the
camptothecin drugs can destroy cancer cells by inhibiting
the proper function of topoisomerase I enZyme,

lecular triplex DNA, intramolecular triplex DNA, four
stranded DNA, Anisomorphic DNA, genomic DNA, nucleo

40

injection, cationic liposomes, virosomes, and receptor

purpose of repairing or enhancing or diminishing the expres
sion of a cellular protein. In addition, the nucleic acid 110
may carry a label (e.g. radioactive label, ?uorescent label or

calorimetric label), these labels serving the purpose of
providing clinical diagnosis relating to the presence or
absence of complementary nucleic acids. Accordingly, the

mediated delivery vehicles. Each of the above gene therapy

vectors contain oligonucleotides Which can act to stabiliZe
the camptothecin drug. The vectors thus serve as a means of 45 nucleic acids or nucleotide polymers can be nucleic acid

delivering stable camptothecin drug to target tissue. The
combination of stable camptothecin drug and gene therapy

polymers including genomic DNA, cDNA, mRNA or oli
gonucleotides containing nucleic acid analogs. An example
of these molecules is provided by the antisense derivatives

has potentially unique and desirable consequences on 110
inhibiting the spread of cancer in humans and animals.
Of the non-viral and viral vectors, liposomes and cationic

as summariZed in a recent revieW (Stein et al., Science

261:1004—1011 (1993) and in US. Pat. Nos. 5,264,423 and
5,276,019, the disclosures of Which are incorporated herein
by reference. Still further, the nucleic acids may encode

lipids have the advantage of being safe, readily reproducible
and easy to manufacture. Liposomes containing oligonucle
otides can more effectively stabiliZe the camptothecin drug
in the antitumor-active lactone form. Oligonucleotide

containing liposomes provide a convenient mode of delivery

55

for combination therapy comprising chemotherapy/gene

The nucleotide polymers can be single-stranded DNA or
RNA, or double-stranded DNA or DNA-RNA hybrid mol

therapy.
In satisfaction of the foregoing objects and advantages,
there is provided by this invention oligonucleotide compo
sitions for delivery of camptothecin drugs. Those composi
tions comprise at least one camptothecin drug in complex

ecules. Examples of double-stranded DNA include structural
genes or genes including control and termination regions, or
60

formation With an oligonucleotide including DNA and RNA
so that the camptothecin drug contains a stabiliZed lactone

lipids, and carbohydrates.

Oligonucleotides

self-replicating systems such as plasmid DNA.
Examples of single-stranded nucleic acids include anti
sense oligonucleotides (complementary to DNA and RNA),

riboZymes and triplex-forming oligonucleotides.

ring. Additionally, the compositions include components
Which comprise viral and non-viral vectors such as proteins,

transcriptional and translational regulatory sequences
including promoter sequences and enhancer sequences
Within the oligonucleotide.

Approaches to enhancing the chemical stabilities of oligo
65

nucleotides have been developed. For enhance stabilities the
single-stranded nucleic acids Will preferably have some or
all of the nucleotide linkages substituted With stable, non

US 6,897,200 B1
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phosphodiester linkages. Such substitutions include

nutrients to the tumor Which in turn facilitates regroWth of
the tumor. Thus it may be considered therapeutically desir
able to treat a patient With anti-angiogenic compounds

phosphorothioate, phosphorodithioate, phosphoroselenate,
or O-alkyl phosphotriester linkages.
The nucleic acids used in the present invention may also
involve nucleic acids in Which modi?cations have been

folloWing reduction of tumor siZe With camptothecin che

made in one or more sugar moieties and/or in one or more

of the pyrimidine or purine bases. Sugar modi?cations can

Genetic material of choice Would be an oligonucleotide
Which sloWs or eliminates the angiogenic process. Such a

include replacement of one or more hydroxyl groups With
halogens, alkyl groups, aZido groups or functionaliZed as

therapeutic approach could involve the use of an oligonucle
otide that reduces or prevents the expression of a key

ethers or esters, and amines. Additionally, complete replace

motherapy.

10

ment of the sugar moiety may be carried out resulting in

sterically and electronically similar structures, including
aZa-sugars and carbocyclic sugar analogs. Examples of
modi?cations in the purine or pyrimidine base moiety

include, for example, alkylated purines and pyrimidines,

15

acylated purines or pyrimidines, or other heterocyclic sub
stitutes knoWn to those of skill in the art.
Our innovation can also use multiple genetic sequences.
In this manner, the sequences for different proteins may be
located on one strand or plasmid. Promoter, enhancer, stress
or chemically-regulated promoters, antibiotic-sensitive or

nutrient-sensitive regions, as Well as therapeutic protein
encoding sequences, may be included into the oligonucle
otide of interest as required. Non-encoding sequences can
also be included in the oligonucleotide of interest.
The nucleic acids employed in the present invention can

absent or produced in diminished quantities in the cancer
patient being treated. The nucleic acids could also reverse
the expression of mutant, non-functional forms of anti
angiogenic proteins. Additionally it may be of interest to use
oligonucleotides such as DNA encoding polypeptides for
secretion from target cells so as to provide for a systemic

effect by the protein encoded by the DNA. Speci?c DNA
molecules of interest include those encoding hemoglobin,
20

interleukin-1, interleukin-2, interleukin-3, interleukin-4,
interleukin-4, interleukin-5, interleukin-6, interleukin-7,
interleukin-8, interleukin-9, interleukin-10, interleukin-11,
etc., GM-CSF, G-CSF, M-CSR, human groWth factor,

25

binding proteins and DNA topology modifying enZymes
such as topoisomerases I, topoisomerase II, topoisomerase
III, LDL receptors, tumor necrosis factor, PDGF, EGF, NGF,

insulin, factor VIII, factor IX, tPA, a variety of nuclear

be isolated from natural sources, or obtained from sources
such as the ATCC or GenBank collections of compounds, or

the nucleic acids can be prepared either by manual or
automated synthetic methods. Synthetic nucleic acids can be

angiogenic protein. Or the oligonucleotide approach could
include genes encoding anti-angiogenic polypeptides either

EPO, [3-globin and the like, as Well as biologically active
mutants of these proteins. The nucleic acid utiliZed may also
30

be antisense DNA or RNA. These antisense molecules can

prepared by a variety of solution or solid-phase reaction

bind to naturally-occurring DNA or RNAWithin the host and

schemes. In general, solid-phase synthesis is the preferred

block the production of molecules Which can counteract,
overcome, or negate the pharmacological effects achieved
by the administration of camptothecins administered in

method. Detailed descriptions of the procedures for solid

phase synthetic methodologies of nucleic acids by
phosphite-triester, phosphotriester, and H-phosphonate

35

oligonucleotide-stabiliZed form.
Further to this concept of co-administration of cytotoxic

chemistries are noW Widely available through out the litera

ture. Examples of solid-phase synthetic methods of nucleic

camptothecins and anti-angiogenic oligonucleotides, pre

acids can be found in the folloWing references: Itakura, US.
Pat. No. 4,401,796; Caruthers, et al., US. Pat. Nos. 4,458,
066 and 4,500,707; Beaucage, et al., Tetrahedron Lett,
22:1859—1862 (1981); Matteucci, et al., J. Am. Chem. Soc.,

vention of blood vessel groWth could be achieved by modu
lating the levels of the numerous types of groWth factors and
proteins involved in the angiogenesis process [Folkman, et

40

al., Science, 235:442—447 (1987)]. These key angiogenic

103:3185—3191 (1981); Caruthers, et al., Genetic

components include, for example, acidic and basic ?broblast

Engineering, 4:1—17 (1982); Jones, chapter 2, Atkinson, et
al., chapter 3, and Sproat, et al., chapter 4, in Oligonacle
otide Synthesis. A Practical Approach, Gait (ed.), IRL Press,
Washington DC. (1984); Froehler, et al., Tetrahedron Lett,

groWth factors (alpha-FGF and beta-FGF), vascular endot
helial groWth factor (VEGF), epidermal groWth factor
(EGF), transforming groWth-factor ot- and [3-(TGF-[3 and
TGF-B), platelet-derived endothelial cell groWth factor (PD
ECGF), platelet-derived groWth factor (PDGF) itself, tumor
necrosis factor ot-(TNF-ot), hepatocyte groWth factor (HGF)
and insulin like groWth factor [See, Klagsbrun, et al., Anna.
Rev Physiol., 53:217—239 (1991) and Folkman, et al., J.

45

27:469—472 (1986); Froehler, et al., Nucleic Acids Res.,
14:5399—5407 (1986); Sinha et al. Tetrahedron Left,
24:5843—5846 (1983); and Sinha, et al., Nucl. Acids Res.,

12:4539—4557 (1984).

50

Nucleic acids Which When introduced into animals or

Biol. Chem. 267:10931—10934 (1992)]. VEGF, or its alter

humans provide physiological effects are included in this

nate designation vascular permeability factor (VPF), has

invention. In this manner nucleic acids can be selected for

also been implicated in the angiogenesis process, and oli
gonucleotides co-administered With camptothecins may also
be useful in modulating VEGF levels and optimiZing the

speci?c therapeutic outcomes that complement or enhance
the therapeutic bene?t Which is achieved by
co-administration of the oligonucleotide-stabiliZed camp

55

anticancer effects of the camptothecins. VEGF is a key

angiogenic protein. Evidence that VEGF stimulates the
angiogenesis in vivo had been developed in experiments

tothecin.

An example of hoW nucleic acid-camptothecin drug
co-administration can be therapeutic is given by the admin
istration of a camptothecin drug With an anti-angiogenic

performed on rat and rabbit cornea (Levy, et al., Growth
60

Factors, 2:9—19 (1989) and Connolly, et al., J. Clin Invest,
84:1470—1478 (1989)), the chorioallantoic membrane
(Ferrara, et al., Biochem Biophys Res Commun.,
161:851—855 (1989)), and the rabbit bone graft model.
Connolly, et al., J Clin Invest, 84:1470—1478 (1989). The

65

nucleotide sequence of numerous peptides and proteins,

oligonucleotide. Upon reaching the tumor site the camptoth
ecin drug can exert its cytotoxic effect and thereby reduce
the tumor siZe by destroying cancer cells. A major cause of
cancer is often the regroWth of the tumor folloWing the ?rst
round of chemotherapy. The regroWth of a tumor folloWing
a course of chemotherapy has been frequently attributed to
vasculariZation of the tumor site, a process Which brings

including angiogenic proteins such as VEGF, are readily
available through a number of computer data bases, for

US 6,897,200 B1
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example, GenBank, EMBL and SWiss-Prot. Through gene
therapy methods, the levels of proteins involved in the

Non-Viral Delivery Vectors

angiogenic process can be modulated and the activities of

injection, gene gun, direct injection, cationic liposomes,
virosomes, and receptor-mediated delivery vehicles. Each of

The non-viral vectors include transfection, naked DNA

oligonucleotide-stabiliZed camptothecin drug delivery
vehicles optimiZed for gains in therapeutic outcomes for the

the above gene therapy vectors contain oligonucleotides

cancer patients.
Antisense RNA molecules can also potentially be used to

Which can act to stabiliZe the camptothecin drug of interest.

optimiZe the therapeutic activities of the camptothecin drugs

camptothecin drug to target tissue. The combination of

The vectors thus serve as a means of delivering stable

stable camptothecin drug and gene therapy has potentially

delivered to the body in a stable form by complexing With
oligonucleotide. Antisense RNA molecules are knoWn to be

10

unique and desirable consequences on inhibiting the spread

effective at regulating translation Within the cell. Using

of cancer in humans and animals.

knoWn methods antisense RNA molecules can be produced
from the corresponding gene sequences. The antisense mol

prior to introduction into animals and humans, the DNA is

To simplify the manipulation and handling of the DNA,

ecules can be used as a therapeutic to regulate gene expres

sion that optimiZes camptothecin activity Within the body.
The antisense molecules are typically designed by studying

15

preferably inserted into a vector, e.g., a plasmid vector such
as pUC118, pBR322, or other knoWn plasmid vectors

the nucleotide sequence, and by reversing the orientation of

[Sambrook, et al., Molecular Cloning: A Laboratory
Manual, Cold Spring Harbor Laboratory press, (1989)]. The

the coding region With regard to the promoter. Accordingly,

plasmid vector may also include a selectable marker such as

the antisense RNA is complementary to the corresponding

the [3-lactamase gene for ampicillin resistance, provided that

mRNA. RevieWs of antisense design can be found elseWhere

the marker polypeptide does not adversely effect the

[Green, et al.,Ann. Rev. Biochem. 55:569—597 (1986)]. The

metabolism of the organism being treated. Additionally, if

antisense sequences can contain modi?ed sugar phosphate
backbones Which is a Widely used approach that alloWs for

enhancer region capable of driving expression of the protein

the increased stabilities of the antisense molecules folloWing
their introduction into humans or animals. The changes in

necessary, the DNA may be operably linked to a promoter/

in the target cell of interest. An example of an appropriate
25

the antisense RNA can also be used to make the antisense

promoter is the cytomegalovirus (CMV) promoter.
Normally, an enhancer is not necessary When the CMV
promoter is used. Other promoters may be used as Well.

molecules less sensitive to RNase activity. Examples of
these types of antisense modi?cations are described by

Certain proteins can be expressed using their native pro

Rossi, et al., Pharmacol, Ther 50(2):245—354, (1991).
Co-complexation of camptothecin drugs With multidrug
resistance (MDR) and/or multidrug resistance-associate pro

moter.

tein (MRP) antisense RNAs Would result in the camptoth

the therapeutic outcome. For example, anti-angiogenic oli

ecin drugs proving to be cytotoxic to the cancer cells and the

gonucleotides can be combined With other genes or their

In certain situations, it may be desirable to use DNA that
encodes tWo or more different proteins in order to optimiZe

riboZymes Would prevent drug resistance from advancing at
the tumor site. Methods for the preparation and use of MDR
and MRP antisense RNAs to modulate drug resistance have

35

encoded gene products to enhance the activity of targeted
cells to camptothecin-based therapies.
Liposomes and cationic liposomes have been Widely used

been reported previously (Gao et al., Anticancer Res. (1998)
18:4 3073—6).

to deliver DNA and antisense oligonucleotides to target

Viral Delivery Vectors

stabiliZed camptothecin drug delivery a liposome or micelles
having at least one membrane comprised of surfactant, lipid

tissues. Here We claim as a vehicle for oligonucleotide

Viral or non-viral vectors can be used to deliver the 40

oligonucleotide-camptothecin drug complexes to the target

or mixture thereof Wherein the membrane de?nes a closed

cells. The viral vectors can include the folloWing:

compartment for holding the camptothecin drug and oligo

retroviruses, adenoviruses, adeno-associated viruses, Herpes
viruses, Vaccinia viruses, and polioviruses.

nucleotide complex. In this compartment the lactone ring of

the camptothecin drug is protected from hydrolysis and fully

consists of tWo 8500-nucleotide RNA molecules nonco

stabiliZed by contributions made by the presence of the
oligonucleotide. The oligonucleotide utiliZed in the present

valently bonded to one another. The virus is enclosed by a
lipid bilayer. Hence the retrovirus can serve as vehicle for
delivering of oligonucleotides to the body, but also as a

invention is selected from a group consisting of DNA and
RNA, as Well as mixtures thereof. Any of the oligonucle
otides mentioned elseWhere in this document could be

vehicle Where camptothecin drugs can be introduced, stored

included in the liposomal preparations.
The present invention provides novel, lipid

Retroviruses contain RNA and DNA. The RNA genome

45

and delivered in a stable manner While being bound in the

tent to cancer cells. In a similar manner, adenoviruses, 55

oligonucleotide-camptothecin drug particles. The liposomes
may comprise synthetic phospholipids, phosphatidic acids,
phosphatidylethanolamines, phosphatidylgylcerols,
phosphatidylserines, polymeriZable phospholipids, phos

active lactone form to the oligonucleotides contained in the
retrovirus. Addition of cationic lipids to retroviruses could

augment the delivery of the drug and oligonucleotide con

SV40, Herpes viruses, Vaccinia viruses, Parvoviruses,

pholipid such as egg phosphatidylcholine, hydrogenated soy

Reoviruses, In?uenza viruses, Vesicular stomatitis virus,
Sindbis virus, poliomyelitis virus, human Wart virus, aden

phosphatidylcholine, distearoylphosphatidylcholine,
dimyristoylphosphatidylcholine,

ovirus are all viruses that contain oligonucleotides that can

distearoylphosphatidylcholine,

serve the multiple roles of complexing, stabiliZing,

diarachidonoylphosphatidylcholine, and may additionally

or

transporting, and delivering camptothecin drugs in humans

comprise cholesterol, for example, in about a 55:45 to 75:25

and animals While also delivering oligonucleotides that are

phospholipid:cholesterol mol ratio. The liposomes may

capable of inducing pharmacological effects that differ from
the camptothecin drugs. The pharmacological effects of the

be about 30 nm to about 10 microns in siZe, preferably about

oligonucleotides contained in the virus particles can

additionally comprise alpha tocopherol. The liposomes can
65

100 to about 300 nm in diameter. The technology can

augment, complement and provide synergism With the

include large unilamellar vesicles or multilamellar

camptothecin drug therapy.

liposomes, or complexes of varying shapes as Well. They can

US 6,897,200 B1
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contain about 0.05 to 200 mg/ml lipid, more preferably
about 5 to about 110 mg/ml lipid. The entrapment of the

become protected from degradation. The liposomes thus
formed are suitable for pharmaceutically acceptable liposo

oligonucleotide-camptothecin drug complex in the lipo

mal formulations Which alloW direct parenteral administra

somes is from about 50% to about 100%, preferably about
90% to about 100%, more preferably about 98 to about
100%. These liposome may be large unilamellar vesicles or

tion of lactone stable oligonucleotide-camptothecin drug
complexes to human patients With cancer. Pharmaceutically
acceptable liposomal formulations Which alloW the direct
oral administration of oligonucleotide-camptothecin drug

multilamellar particles. The liposomes may be homoge

complexes to human patients With cancer and other disease

neous or unimodal With regard to siZe distribution.

Pharmaceutical preparations containing the

oligonucleotide-camptothecin drug complex entrapped in

states are also claimed in the current invention.
10

Brie?y, one method of forming lipid-oligonucleotide

the liposomes and pharmaceutically acceptable carriers or

camptothecin drug particles involves contacting an oligo

diluents are another embodiment of the present invention.

nucleotide solution and a camptothecin drug solution to

The liposome compositions of the invention may be used to
treat cancer. In related applications, the liposomal formula

form a oligonucleotide-camptothecin drug complex solution

then contacting that oligonucleotide-camptothecin drug

tions can be used prophylactically to prevent the onset or 15 complex solution With a solution of lipids and a detergent to
recurrence of a cancer. The composition of the present
form a oligonucleotide-camptothecin drug-lipid mixture,

folloWed by removal of the detergent or organic solvent.
Another method involves ?rst forming the liposomes con

invention is, for example, provided also as a three

component system. The three component system comprises
empty liposomes in a solution ranging from about pH 3.0 to

pH 8.0, and the oligonucleotide-camptothecin drug com

20

plex. The solution can be acetic acid buffer, oxalic acid
buffer, or succinic acid buffer, preferably aqueous citric acid
buffer. The basic solution is preferably sodium carbonate.

somes are then admixed With a solution containing lipophilic

camptothecin drugs that can partition into the pre-formed

particles or ioniZable, amine-containing camptothecin drugs

The complex to lipid Weight ratio is greater than about 0.1:1
to about 3:1.

25

PolymeriZable phospholipids that can be used in this

include polymeriZable double-bond containing monomeric
phospholipids. The polymeriZable phospholipids to be used
30

the solution comprising of from about 15—35% Water and
about 65—85% organic solvent and the amount of cationic

lipids being sufficient to produce a +/— charge ratio of from

contain, but need not be limited to, the following:
diacetylenes, ole?ns, acetylenes, and thiols as Well. The
polymeriZation process can be initiated by free radical
initiators such as aZo-bis-isobutyronitrile (AIBN) or other
initiators as Well including aZo-bis-amidinopropane

that can accumulate in the liposomal particle in response to
the ion gradient across the liposomal membrane. Another

method of forming lipid-nucleic add particles involves the
folloWing: 1) contacting an amount of cationic lipids With
oligonucleotide-camptothecin drug complex in a solution; 2)

in this invention must contain at least one polymeriZable

moiety, but may include several polymeriZable groups as
Well. PolymeriZable groups located in the phospholipids can

taining oligonucleotide in aqueous medium, preferably a
buffer, then acidifying or alkaliniZing the medium, thereby
establishing a pH or chemical gradient. The resulting lipo

about 0.1 to about 200.

To provide a hydrophobic, charge-neutraliZed lipid
35

oligonucleotide-camptothecin drug complex, the folloWing

dihydrochloride). Other methods of initiating polymeriZa

procedure can be used: contacting the hydrophobic, charge
neutraliZed lipid-oligonucleotide-camptothecin drug com

tion include using ultraviolet light or gamma irradiation.

plex in solution With non-cationic lipids, to provide a

lipid-oligonucleotide-camptothecin drug complex mixture;

The liposome compositions may be prepared by remote
loading techniques, Which rely on a pH or chemical gradient
across the liposome bilayer to load camptothecin drugs into

40

liposomes containing oligonucleotide-camptothecin drug

and removing the organic solvents from the lipid
oligonucleotide-camptothecin drug complex mixture to pro
vide lipid-oligonucleotide-camptothecin drug complex par

complexes isolated or in contact With the lipid matrix. A?rst

ticles in Which the nucleic acids are protected from

step Would involve forming the oligonucleotide-containing

degradation and the oligonucleotide-drug complexes aid in

liposomes in a aqueous medium, preferably a buffer. The
solution outside the liposomes is then exchanged or modi

45

stabiliZing the drug.
The folloWing lipids can be used in the formation of

?ed by acidifying or alkaliniZing the medium, thereby

camptothecin-lipid-oligonucleotide complexes: DC-Chol,

establishing a pH or chemical gradient. Care is taken not to

3B-(N—(N‘,N‘-dimethylaminoethane)carbamoyl)

subject the liposomal particles to osmotic stress through
these manipulations. The resulting liposomes are then

cholesterol (see, Gao, et al., Biochem. Biophys. Res. Comm.

179;2s0_2s5 (1991)); DDAB, N,N-distearyl-N,N
dimethylammonium bromide; DMRIE, N-(1,2

admixed With the camptothecin drugs, Which can be pre

dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl

pared by contacting the liposomal-oligonucleotide solution
and camptothecin drug solution, or liposome compositions
may be prepared from oligonucleotide-camptothecin drug
complex and lipids in either detergent-based or organic
solvent-based systems, folloWed by removal of the detergent
or organic solvent, leading to particle formation.
The liposomes of the invention may be dehydrated, either

ammonium bromide; DODAC, N,N-dioleyl-N,N
55

dioleyloxy)propyl)-N-(2-(sperminecarboxamido)ethyl)-N,

prior to or folloWing the establishment of the remote loading

techniques, Which rely on a pH (Biochim. Biophys. Acta,
857, 123, 1986) or chemical gradient (J. Natl. Cancer Inst,
81, 1484, 1989). Thus, the present invention provides meth
ods of preparing oligonucleotide-camptothecin drug par

60

therapy. Within a liposomal formulation both the oligonucle

otides and oligonucleotide-camptothecin drug complexes

N-dimethylammonium tri?uoroacetate; DOTAP, N-(1-(2,3
dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride;
DOTMA, N-(1-(2,3-dioleyloxy)propyl)-N,N,N
trimethylammonium chloride; ESM, egg sphingomyelin.
The term “lipid” refers to any suitable material resulting in

macromolecular assembly such as bilayer, monolayer, lipid
DNA complex, such that a hydrophobic portion of the lipid

ticles Which are useful for the therapeutic delivery of oli

gonucleotide and camptothecin drugs for combination

dimethylammonium chloride; DOGS, diheptadecylami
doglycyl
spermidine;
DOPE,
1,2-sn
dioleoylphoshatidylethanolamine; DOSPA, N-(1-(2,3
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material orients toWard the monolayer, bilayer, or DNA

lipid complex While a hydrophilic portion orients toWard the
aqueous phase. Amphipathic lipids are necessary for the
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formation of the primary lipid vesicle structural element.
Hydrophilic characteristics of these agents derive from the

The term “hydrophobic” as applied to DNA and DNA

complexes implies complexes Which are substantially more

presence of phosphate, carboxylic, sulfato, amino,
sulfhydryl, nitro, and other similar functionalities. Hydro

soluble in organic solvents than in aqueous solutions. More
particularly, hydrophobic DNA and DNA complexes are
aggregates Which are at least 40% soluble in organic sol
vents such as chloroform/methanol mixtures, and preferably

phobicity in the lipids can be conferred by the inclusion of
groups that include, but are not limited to, long chain
saturated and unsaturated aliphatic hydrocarbon groups, and

more than 80% soluble, more preferably more than 90%

groups substituted With one or more aromatic, cycloaliphatic

or heterocyclic groups. The term “neutral lipid” refers to any
of a number of lipid species Which exist either as uncharged

or neutral ZWitterionic species at physiological pH. The
group of neutral lipids are comprised of amphiphiles such as

soluble in such organic solvents.
The current invention can employ formulations With
10

mellar vesicles (LUVs), and small unilamellar vesicles
(SUVs) at concentrations ranging from 0.5 mg/ml to 200
mg/ml can be prepared through a hydration process. Lyo

diacylphosphatidylcholine,
diacylphosphatidylethanolamine, ceramide, sphingomyelin,
cephalin, and cerebrosides.
The term “non-cationic lipid” refers to any neutral lipid as
described above as Well as anionic lipids. Examples of

15

drug-lipid complexes Will be obtained by freeZe-drying
solutions containing these ingredients in mixtures of
20

GIBCO/BRL, Grand Island, N.Y., USA); LIPO
FECTAMINE (commercially available cationic liposomes
comprising DOSPA and DOPE, from GIBCO/BRL); and
TRANSFECTAM (commercially available cationic lipids
comprising DOGS in ethanol from Promega Corp.,
Madison, Wis, USA). This invention can also employ
polymeriZable phospholipids Where polymeriZable moieties
are included in the headgroup region of the phospholipid
and/or in the acyl chain region of the phospholipid.

t-butanol and Water (drug:lipid ratios in the range of 1:10 to

1:200 Would be desirable). In light of the high levels of
lipophilicity that We have observed in some of the neW

analogues (KDMPC=8,000 M-1 versus KDMPC=1M_1 for
other camptothecins), the camptothecin drugs Will have the

Which can be used in the present invention. These include,

for example, LIPOFECTIN (commercially available cat
ionic liposomes comprising DOTMA and DOPE, from

philiZed formulations of liposomal oligonucleotide
camptothecin drug-lipid can be employed in this invention
as Well. Vials containing the oligonucleotide-camptothecin

anionic lipids include the folloWing: cardiolipin, diacylphos
phatidylserine and diacylphosphatidic acid. The term “cat
ionic lipid” refers to any of a number of lipid species Which
carry a net positive charge at physiological pH. Such lipids
include, but are not limited to, DODAC, DOTMA, DDAB,
DOTAP, DC-Chol and DMRIE. Additionally, a number of
commercial preparations of cationic lipids are available

lipids exhibiting different transition temperatures and
vesicles siZes. Multilamellar vesicles (MLVs), large unila

25

ability to interact With the liposomal particles in a number of
different Ways, dependent upon the individual drug struc
ture. FolloWing lyophiliZation, the liposomes for i.v. admin
istration Will be reconstituted by adding PBS to the vial

containing lyophiliZed particles and mixing for several min
30 utes.
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The term “transfection” as used herein, refers to the

The folloWing lipid combinations and particle types are
suitable for use in this invention: Egg-PC/Cholesterol (SUV,
LUV and MLV); DPPC/DPPG/cholesterol (SUV, LUV and
MLV ratio 8:5:4 or thereabout); DPPC/DPPG (SUV, LUV
and MLV; lipid ration of 5:2 or thereabout); DMPC:DMPG
(SUV, LUV, MLV; lipid ratio of 14:1 or thereabout); Egg

introduction of polyanionic materials, particularly nucleic

PC/Egg PG/Cholesterol (SUV, LUV and MLV; lipid ratios

acids, into cells. The term “lipofection” refers to the delivery
of such materials using liposome complexes to cells. The

of 4:2:1 or thereabout); DSPC/DSPG/gm 1/Sphingomyelin
Cholesterol (SUV and MLV; ratio 8:5:4:1:1 or thereabout);
DPPC/DPPA (SUV and MLV; lipid ratio of 5:6:2 or

polyanionic materials can be in the form of RNA or DNA

40

incorporated into expression vectors. The involvement of

thereabout); DMPC:DMPA (SUV, LUV, MLV; lipid ratio of

expression vectors facilitates gene expression folloWing

14: 1 or thereabout); HPC/PEG (MLV and SUV; lipid ratio of
5:1 or thereabout); Egg-PG/Cholesterol (SUV, LUV and
MLV; lipid ratio 2:1 or thereabout); DPPG/cholesterol

entry into the cell. Polyanionic material can be used in the
present invention and is meant to include oligonucleotides

having coding sequences for structural proteins, receptors

45

and hormones, as Well as transcriptional and translational

regulatory elements (i.e., promoters, enhancers, terminators

(SUV, LUV and MLV ratio 8:4 or thereabout); DPPG/DPPA
(SUV, LUV and MLV; lipid ration of 5:1 or thereabout);
DMPC:DSPC (SUV, LUV, MLV; lipid ratio of 14:1 or

and signal sequences) and vector sequences. Incorporation

thereabout); Egg-PC/Egg PG/Cholesterol/DPPA (SUV,

of particular nucleic acids into expression vectors are knoWn
methods to those of skill in the art, but are described in detail

LUV and MLV; lipid ratios of 4:2:1:1 or thereabout);

DMPC/DSPC/Sphingomyelin/Cholesterol (SUV, LUV and
MLV; ratio 8:5:4::1 or thereabout); DPPC/egg PE (SUV,

elseWhere, for example: Sambrook et al., Molecular Clon

ing.'A Laboratory Manual (2nd ed.), Vols. 1—3, Cold Spring

LUV and MLV; lipid ratio of 5:2 or thereabout); DMPC:D

Harbor Laboratory, (1989) or Current Protocols in Molecu
lar Biology, F. Ausubel et al., ed. Greene Publishing and
Wiley-Interscience, NeW York (1987), both of Which are

MPA:DSPC (SUV, LUV, MLV; lipid ratio of 14:1:3); HPC/
cholesterol (MLV, LUV and SUV; lipid ratio of 5:1 or
55

incorporated herein by reference. The terms “expression

The drug/lipid mixtures can be prepared in a suitable
solvent such as chloroform and then dried under a stream of

vectors”, “cloning vectors”, or “vectors” are used to refer to
plasmids or other nucleic acid-derived materials that are able
to replicate in a chosen host cell. Expression vectors may

replicate autonomously, or they may replicate by being

nitrogen gas. Lipid ?lms resulting from this process can then
60

inserted into the genome of the host cell, and these methods

for a vector to be usable in a variety of cell types, e.g.,

particularly in mammalian cells.

be dried under high vacuum for 1—24 hrs. to properly assure
the removal of trace chloroform. Dried lipid/drug ?lms can
be hydrated in solutions of varying pH values. In some cases

liposome preparations can be froZen/thaWed several times
prior to extrusion through stacked polycarbonate ?lters of

are Well knoWn to those experienced in the art. Vectors that

replicate autonomously Will have an origin of replication or
autonomous replicating sequence (ARS) that is functional in
the target cells and tissues of interest. Often, it is desirable

thereabout).
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speci?c pore siZe to reduce the particle siZe. In some cases
MLVs Will be sonicated to prepare small MLVs and SUVs.

During formulations samples can be heated to approxi
mately 1 to 10° C. above the thermotropic phase transition

US 6,897,200 B1
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temperatures of the phospholipids contained in the prepa

tothecin lactone forms to DNA that result in stabiliZation of

rations prior to the extrusion or sonication process. Particle

the active forms of the drug, oligonucleotide-camptothecin

sizing of the preparations can be performed using commer
cially available particle siZers such as instruments made by

polyamine-lipid complexes should exhibit favorable in?u

drug-polyamines and oligonucleotide-camptothecin drug
ences on the drugs by acting to conserve the active lactone
forms.

Malvern or Coulter.

Cationic Amphiphiles and Polyamines

Cyclodextrins

The cationic amphiphiles are often effective at transport

ing biologically-active therapeutics into cells. Additionally,
targeting of organs for gene therapy by intravenous admin
istration of therapeutic compositions can be achieved using
such systems (as described in US. Pat. No. 5,719,131).
Lipophilic groups of amphiphiles can be derivatives of
steroids, functionaliZed amines, or derived from alkyl or
acyl groups; and the cationic groups can by amines of
modi?ed amines, or polyalkylamines, Which may be proto
nated at physiological pH. The therapeutic formulations are

Cyclodextrins can be used as cellular delivery systems for

oligonucleotide-camptothecin-drug complexes. Oligonucle
10

otides can bind noncovalently With substituted and non

substituted beta gamma cyclodextrin and derivatives. The
uptake of oligonucleotides into cells can be modulated With

cyclodextrin. The pharmaceutical formulation of

oligonucleotide-camptothecin drug complex With cyclodex
15

prepared by contacting a dispersion of cationic amphiphiles

trin and oligonucleotide-camptothecin-lipid complex can
render a physiologically acceptable carrier. The inclusion of

cyclodextrins in camptothecin-lipid complexes can impact
on biological activities by increasing the cellular uptake and

With the biologically-active molecules: in the present inven
tion described herein it is camptothecin drugs in combina
tion With DNA. Oligonucleotide-camptothecin drug com
plexes can be delivered to cells and this process can be

accumulation of both the active lactone form of camptoth
ecin drug and of the exogenous oligonucleotide included in
the formulation. The formulations can be of potential utility

facilitated using cationic amphiphiles. Representative uses

in diseases such as cancer, infectious diseases such as in the

of the therapeutic compositions containing lipid, oligonucle

case of viral infections, and in?ammation. Formulation of

otides and cationic amphiphiles are as folloWs: gene therapy,

anticancer therapy, diseases involving in?ammation and

25

infectious diseases. The oligonucleotide therapeutics are
provided in the form of a plasmid in combination With

oligonucleotide-camptothecin drug complexes and
camptothecin-lipid-oligonucleotide complexes With cyclo
dextrins may be useful in increasing the solubility and

stability of an oligonucleotide-camptothecin drug complex

camptothecin drugs, and cationic amphiphiles capable of
interacting With both the lipid, oligonucleotide and

in vitro and in vivo.

Camptothecin Drugs

oligonucleotide-camptothecin drug complex.

Preferably, the camptothecin drugs utiliZed in this inven

Certain amphiphiles and neutral molecules as Well can

tion are any of the knoWn camptothecin drugs found in the

covalently associate With macromolecules. An important

prior art to have the necessary liposomal loading, loW
toxicity and high antitumor activity for the intended pur
pose. Examples of the camptothecin drugs that may be

example of these types of agents are photosensitiZers. These

agents are exempli?ed by prophyrin-based photosensitiZers,

including prophyrins, chlorins, bacteriochlorins, polypyr

35

utiliZed include:

rolic macrocycles phthalocyanines. The photosensitiZers,
especially prophyrins can conjugate biomolecules, including
biological active molecules such as steroids, lipids, peptides,

nucleosides, nucleotides, antibody conjugates, steroid
conjugates, sugar conjugates, and mono and polynucleotide
conjugates. Peptides along With other compounds such as

40

membrane transport molecules and DNA ligands can also be

conjugated. The photosensitiZers can be activated by light in
order to covalently bind the agent to DNA. The camptoth
ecins can be photoactivated and complexed to DNA as Well

45

(Leteurtre et al., 1993). This invention claims

oligonucleotide-camptothecin complexes and

A) Wherein R is N02, NH2, N3 hydrogen,

oligonucleotide-camptothecin drug in combination With
other drugs Where the agents have been covalently attached
using light. Such covalently modi?ed aggregates may
exhibit improvements in terms of stabiliZing and delivering

trimethylsilylmethylaminomethyl, halogen (F, Cl, Br,
I)>COOH, OH, O—C1_3 alkyl, SH, S—C1_3 alkyl CN,
CH2 NH2, NH—C1_3 alkyl CH2—NH—C1_3 alkyl,

N(C1_3 alkyl)2, OCH2CH2N(CH2CH2OH)2,

the active agents to the tumor. Such covalently attached
molecules useful for the desired purposes undergo disas

NHCH2CH2N(CH2CH2OH), and SCHZCHZN

sembly upon reaching the tumor site thereby releasing active
agent.

NHCH2CH2CH2N(CH2CH2OH)2 and SCHZCHZCHZN

(CH2CH2OH)2, OCH2CH2CH2N(CH2CH2OH)2,
55

Polyamines can be used as carriers for oligonucleotide

camptothecin drug complexes. Polyamines are ubiquitous

(CH2CH2OH)2, OCH2CH2N(CH2CH2CH2OH)2,
NHCH2CH2N(CH2CH2CH2OH)2 and SCHZCHZN

cell components, and these agents are essential for normal

(CH2CH2CH2OH)2,
OCH2CH2CH2N(CH2CH2CH2OH)2, NHCH2CH2CH2N

groWth. Polyamine analogues, notably those With ethyl or

(CHZCHZCHZOH)2

benZyl groups on the terminal nitrogen atoms, have potent
antiproliferative activity and are promising agents for the

(CHZCHZCHZOH), OCH2CH2N(C1_3 alkyl)2,

and

SCHZCHZCHZN

NHCH2CH2N(C1_3 alkyl)2 and SCH2CH2N(C1_3 alkyl)2,

treatment of cancer. The association of cad onic polyamines

OCH2CH2CH2N(C1_3 alkyl)2, NHCH2CH2CH2N(C1_3

With negatively-charged oligonucleotides induces signi?

alkyl)2- and SCH2CH2CH2N(C1_3alkyl)2, CHO or C1_3

cant structural changes in the macromolecules in cell-free

alkyl and Z is H, C1_8 alkyl, trimethylsilyl,

systems. Spermine and spermidine can cause DNA to con 65
dense and aggregate and induce transition as in B-to-Z in

tertbutyldimethylsilyl, trimethylsilylmethyl, trimethylsi
lymethylaminomethyl t-butyldimethylsilylethyl,
trimethylsilylethyl,

certain DNA sequences. Because it is the binding of camp
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trimethylsilylmethyl,
trimethylsilylmethylaminomethyl,
t-butyldimethylsilylethyl, trimethylsilylethyl,

15

or CH2NR1R2 Where (a) R1 and R2 are, independently,

hydrogen, C1_6 alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl-C2_
6, alkenyl, hydroXy-C1_6 alkyl CL6 alkoXy CL6 alkyl

or CHZNRJLR2 Where (a) R1 and R2 are, independently,

5,6,7-membered heterocyclic rings contains one or more

hydrogen, C1_6 alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl
C2_6 alkenyl, hydroXy-C1_6alkoXy, CL6 alkoXy C1_6-alkyl,

O, N, S (b)R1 is hydrogen, CL6 alkyl, C3_7 cycloalkyl,

C3_7 cycloall<yl-C1_6 alkyl, C2_6 alkenyl, hydroXy-C1_6
alkyl or C1_6 alkoXy-C1_6 alkyl and R2 is —COR3 Where

R3 is hydrogen, CL6 alkyl, perhalo-C1_6 alkyl, C3_7
cycloalkyl-C3_7 cycloall<yl-C1_6 alkyl, C2_6 alkenyl,
hydroXy-C1_6 alkyl, CL6 alkoXy, CL6 alkoXy-C1_6alkyl, or

5,6,7-membered heterocyclic rings contains one or more
25

alkyl or CL6 alkoXy-C1_6 alkyl and R2 is —COR3 Where

R3 is hydrogen, CL6 alkyl, perhalo-C1_6 alkyl, C3_7
cycloalkyl, C3_7 cycloalkyl-C1_6 alkyl, C2_6 alkenyl,
hydroXy-C1_6 alkyl, C1_6 alkoXy, C1_6 alkoXy-C, alkyl, or

(c) R1 and R2 taken together With the nitrogen atom to
Which they are attached form a saturated 3—7 membered

heterocyclic ring Which may contain a O, S or NR4 group,

(c) R1 and R2 taken together With the nitrogen atom to

Where R4 is hydrogen, CL6 alkyl, perhalo-C1_6 alkyl, aryl,

Which they are attached form a saturated 3—7 membered

aryl substituted With one or more groups selected from the

group consisting of C1_6 alkyl, halogen nitro amino, CL6

alkylamino, perhalo-C1_6 alkyl, hydro-CL6 alkyl, CL6

heterocyclic ring Which may contain a O, S or NR4 group,
35

Where R4 is hydrogen, C1_6 alkyl, perhalo-C1_6 alkyl, aryl,
aryl substituted With one or more groups selected from the

alkoXy, CL6 alkoXy-C1_6alkyl and —COR5 Where R5 is

group consisting of CL6 alkyl, halogen, nitro, amino, CL6

hydrogen, C1_6 alkyl, perhalo-C1_6 alkyl, C1_6 alkoXy, aryl

alkylamino, perhalo-C1_6 alkyl, hydroXy-C1_6 alkyl, CL6

and aryl substituted With one or more C1_6alkyl, perhalo

CL6 alkyl, hydroXy-C1_6alkyl, or CL6 alkoXy-C1_4 alkyl

O, N, S (b)R1 is hydrogen, CL6 alkyl, C3_7 cycloalkyl,
C3_7cycloalkyl-C1_6 alkyl, C2_6 alkenyl, hydroXy-C1_6

40

groups. In the structure shoWn above, n is an integer of 1

alkoXy, C1_6 alkoXy-C1_6 alkyl and —COR5 Where R1 is

hydrogen, CL6 alkyl, perhalo-C1_6 alkyl, CL6 alkoXy,
aryl, and aryl substituted With one or more CL6 alkyl,

or 2. Preferred aryl groups are phenyl and naphthyl;

perhalo-C1_6 alkyl, hydroXy-C1_6alkyl, or C1_6 alkoXy
45

CL6 alkyl groups. In the structure shoWn above, n is an
integer of 1 or 2. Preferred aryl groups are phenyl and

naphthyl;
C. Additional camptothecin compounds of the present
invention have the hydroXyl group at the 20-position
esteri?ed With:—Aromatic and aliphatic carboXylic acids,
aliphatic carboXylic acid With the formula —O(CO)—
(CH2)m—CH3, Where m=1—20, and polyethers; O-PEG
OH (MW=350—5000), O-PEG-OMe (MW=350—5000), -

alpha-carboXyl group of a naturally occurring amino acid

B) Wherein R6 is hydrogen, cyano, formyl, hydroXy, CL8

alkoXy, nitro, amino, halogen (I Br, Cl, F), C1_8 alkyl,
tri?uoromethyl, trimethylsilylmethylamino,
aminomethyl, aZido, amido, hydraZino,

55

to form a group of the formula —OC(O)—CH2)m—

NRloRll, Where m=1—6 or —OC(O)CHR9NR1OR11,
Where R9 is the side chain of one of the naturally

occurring ot-amino acids, R10 and R11 are, independently,
hydrogen or C1_8, alkyl. Suitable side chains R9 are the
side chains of the amino acids glycine, alanine, valine,

leucine, isoleucine, phenylalanine tryptophan, lysine,
arginine, histidine, aspartate, glutamate, asparagine,
glutamine, cysteine and methionine. Particularly pre
—OC(O)R7 or OC(O)—NR7R8, Where R7 and R8 are,
independently hydrogen or C1_8 alkyl; and Z is H, CL8

alkyl, trimethylsilyl, tertbutyldimethylsilyl,
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ferred esters are glycinate esters. These esters are pro

drugs Which are converted to the camptothecin compound

by hydrolysis of the ester bond;

